Comparison of Topical Travoprost Eye Drops Given Once Daily and Timolol 0.5% Given Twice Daily in Patients with Open-Angle Glaucoma or Ocular Hypertension

Goldberg, Ivan; Cunha-Vaz, Josè; Jakobsen, Jan Erik; Nordmann, J.–P.; Trost, E; Sullivan, Emily

doi:10.1097/00061198-200110000-00010

Cited by 111 publications

(65 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most common side effect with bimatoprost was trace to mild conjunctival hyperemia that was considered as cosmetic rather than a safety issue without any sequelae [29,30,31,32,33]. Other studies by Goldberg et al [34] and Netland et al [35] have shown that the most frequent adverse event with the use of travoprost was also ocular hyperemia which was experienced in low grade and did not appear to pose any safety issues to the patient or interfere with daily activities.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Alagöz

Bayer²,

Boran³

et al. 2008

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare the subjective symptoms, conjunctival hyperemia, tearing response and conjunctival cytological changes secondary to topical administration of bimatoprost and travoprost for 6 months. Methods: Newly diagnosed primary open-angle glaucoma patients were randomly prescribed bimatoprost (35 cases) or travoprost (42 cases). Two patients in each group were excluded because they did not appear at their appointments regularly. Thus, 33 and 40 patients completed the study in the bimatoprost and travoprost groups, respectively. Redness, itching, foreign-body sensation, pain and discomfort were assessed by a questionnaire, and patients were examined for conjunctival hyperemia. Schirmer’s I and break-up time tests were performed, and impression cytology of conjunctiva was evaluated. Results: Subjective symptoms were similar in both groups. The only subjective symptom that changed significantly was redness. The change in conjunctival hyperemia along the study period correlated with the patient-reported redness in both groups, being highest on day 30. Schirmer’s test I and break-up time did not change with time and were similar in both groups. The impression cytology grade increased with time in both groups with the only significant difference between groups on day 90 (higher in the bimatoprost group). Conclusion: We observed conjunctival hyperemia as the most common side effect of bimatoprost and travoprost. Tear film functions were not affected by these drugs while cytological alterations were.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Alagöz

Bayer²,

Boran³

et al. 2008

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Another study confirmed that travoprost has a significantly greater effect than timolol on intraocular pressure. 2 More than 37% of patients may experience ocular hyperaemia while taking travoprost. This occurs more frequently than in patients using latanoprost or timolol.…”

Section: Editorial Officementioning

confidence: 99%

New Drugs: Travoprost

2002

Aust Prescr

View full text Add to dashboard Cite

“…27 It has been proven effective in IOP reduction as both monotherapy and combination therapy. [28][29][30] Travoprost is a selective F 2α (FP) prostaglandin receptor agonist and is the isopropyl ester of the positive enantiomer of fluprostenol (a selective FP prostanoid receptor agonist). 31 After being absorbed by the cornea, the prodrug is hydrolyzed by corneal esterases forming the active free acid AL-5848.…”

Section: Introduction To Travoprost-timololmentioning

confidence: 99%

“…29,30 The plasma half-life of travoprost is 45 minutes. An IOP reduction is detectable at two hours post dose and peaks at ∼12 hours.…”

mentioning

confidence: 99%

Safety and Efficacy of Fixed Combination Travoprost-Timolol in the Lowering of Intraocular Pressure

Noecker

Pokabla

2010

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Abstract:The fixed combination eye drop Duotrav is a combination of travoprost 0.004% and timolol maleate 0.5%. Both travoprost and timolol have been used separately for the treatment of glaucoma by lowering intraocular pressure. Multiple studies have demonstrated the efficacy and safety of the fixed combination travoprost/timolol for the treatment of open-angle glaucoma and ocular hypertension. The once daily dosing of this combination offers multiple potential advantages such as patient adherence, potential cost advantages, and reduction in exposure to preservatives. This article discusses the benefits of fixed combination medications and summarizes past and recent studies listed on the online resource PubMed of the fixed combination travoprost/timolol with comparison to both monotherapy and other similar fixed combination ocular hypotensive preparations.

show abstract

Comparison of Topical Travoprost Eye Drops Given Once Daily and Timolol 0.5% Given Twice Daily in Patients with Open-Angle Glaucoma or Ocular Hypertension

Abstract: Travoprost 0.004% reduced diurnal mean intraocular pressure significantly more than timolol 0.5%. Both concentrations of travoprost were well tolerated and safe for use in patients with open-angle glaucoma or ocular hypertension.

Cited by 111 publications

References 12 publications

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

New Drugs: Travoprost

Safety and Efficacy of Fixed Combination Travoprost-Timolol in the Lowering of Intraocular Pressure

Contact Info

Product

Resources

About